Smallpox Market Forecast, Market Shares-Ken Research

1
The First Drug To Treat Smallpox Market Outlook
Ken Research
2
Smallpox is an extremely contagious infection
caused by the Variola virus for which there is no
known cure. Symptoms include fever, malaise,
abdominal and severe back pain. The last known
natural case occurred in Somalia in 1977 and due
to worldwide vaccination programs, this disease
has been completely eradicated. By 1980 the WHO
declared that smallpox had completely been
eradicated although government and health
agencies still have stashes of smallpox virus for
research purposes. Nowadays people no longer
receive routine smallpox vaccinations as they can
have potentially fatal side effects, so only the
people that face a high risk of exposure get the
vaccine. According to the study, Smallpox
Pipeline Review, H2 2018, researchers are still
carrying out studies on smallpox and its
treatments. Since smallpox virus is deadly and
contagious the research projects are carried out
under extreme authorization. The US Centers for
Disease Control and Prevention along with the
Russian State Centre for Research on Virology and
Biotechnology are the only two labs in the world
approved and known to have smallpox virus.
Recently the US Food and Drug Administration
(FDA) approved the first drug to treat smallpox.
This comes as there is a growing concern that
the small pox virus may be used in bioterror
attacks by terrorists or by people with criminal
intentions.
3
This is the main reason why the FDA gave priority
review to TPOXX, asmall-molecule antiviral
treatment made by the US based SIGA Technologies
Inc. and approval was based on research treating
animals infected with viruses that were closely
related to the virus causing smallpox. Out of the
animals tested, less thanone-tenth died compared
to the one-third fatality rate among humans who
got infected and did not consume the drug. Until
now, smallpox treatment consisted of managing
symptoms and treatment with three antivirals that
are not proven to treat the disease but have been
the best potential line of defense. In addition,
the vaccine would be used to prevent the disease
from spreading. TPOXX is the first approved
treatment specifically initiated for the
treatment of this virus. Investigators in the
Department of Molecular Virology and Microbiology
(MVM), at the Baylor College of Medicine in the
US, have received funding from several sources to
study the immune responses to the smallpox virus
and for vaccine development studies. This shows
that authorities around the world are still
concerned about this disease. MVM scientists
have also investigated the vulnerability of the
general population to smallpox and found that the
discontinuation of the smallpox vaccination
program in the early 1970s has reduced immunity
to the variola virus in the general population.
In another project MVM researchers have applied a
new technology to identify the vaccinia virus
antigens that are responsible for the
anti-smallpox humoral and immunity that grants
protection against smallpox infection.
4
The technology used is called the TAP
(Transcriptionally Active PCR) Express TM system
and is a tool that allows thousands of antigen
genes to be individually amplified so that their
biological function or DNA vaccine immunological
potency can be quickly analyzed. The goal of this
work has been to identify antigens that would be
candidates for use in developing new smallpox
vaccines.Also, a team led by the virologists of
the University of Alberta in Edmonton, Canada are
trying to recreate Variola, the small pox causing
virus in order to better understand it. All
around the world there is growing concern
regarding the potentially destructive uses of the
smallpox virus. Research institutions, mainly
from the US, are constantly trying to develop new
drugs and vaccines to combat smallpox. Certain
educational institutions are also assisting in
the process besides Canadian contributions. For
more information on the research report, refer to
below link- https//www.kenresearch.com/healthcar
e/pharmaceuticals/smallpox-pipeline-review/152640-
91.html Related Report- https//www.kenresearch
.com/healthcare/pharmaceuticals/smallpox-h1/25199-
91.html
5
Contact Us Ken ResearchAnkur Gupta, Head
Marketing CommunicationsSales_at_kenresearch.com
91-9015378249
6
(No Transcript)